Bioworld

GSK gaining rights to Hutchmed’s KRAS/EFGR drug in $1.295B deal

GSK plc is moving further into antibody-drug conjugates, taking ex-China rights to Hutchmed Ltd.’s HMPL-A830 in a deal worth up to $1.295 billio…

Sanofi looks to Revolution-ize precision oncology in global SHP2 partnership

We're enjoying the one-two punch, Mark Goldsmith, president and CEO of Revolution Medicines Inc., told BioWorld after the Redwood City, Calif.-b…

Duke-NUS brings aboard Novo Nordisk to fund stem cell research program

HONG KONG – Denmark's Novo Nordisk A/S has teamed up with Singapore's Duke-NUS Medical School to provide funding for the next three to five year…